Priming of beta-2 agonist and antimuscarinic induced physiological responses induced by 1200Â mg/day NAC in moderate to severe COPD patients: A pilot study

The treatment with 1200 mg/day NAC has potential to enhance the bronchodilator ability of antimuscarinic-agents but not beta-2-agonist. However, its clinical application has to be established in large sample-size studies for longer-duration.